• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

RECA-1 Antibody – Mouse Monoclonal

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS213213

MBS213213 is an antibody targeting RECA-1. Also known as MOUSE ANTI RAT RECA-1. Host: Mouse. More details

$635 / 0.25 mg +1 FREE 8GB USB
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
RECA-1, Monoclonal Antibody
Full Product Name
MOUSE ANTI RAT RECA-1
Product Gene Name
Clonality
Monoclonal
Isotype
IgG1
Clone Number
HIS52
Host
Mouse
Form/Format
Purified
Purified IgG - liquid
Concentration
IgG concentration 0.5 mg/ml (lot specific)
Preparation and Storage
Store at 4 degree C or at -20 degree C if preferred. This product should be stored undiluted. Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life: 18 months from date of despatch.
Perservative Stabilisers
0.09% Sodium Azide
Preparation||Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Immunogen
Stromal cells from rat lymph node
Fusion Partners||Spleen cells from immunised mice were fused with cells of the SP2/0 mouse myeloma cell line.
Buffer Solution||Phosphate buffered saline
Target Species
Rat
Applications Tested/Suitable for anti-RECA-1 antibody
Immunohistology Frozen, Immunofluorescence (IF)

Testing Data of anti-RECA-1 antibody

Published customer image:hADSCs led to the appearance of perivascular spaces in between endothelial and astrocytic basement membranes one week after injection. A -D) Confocal images of horizontal sections immunostained with anti-pan-laminin antibody (red) one week after injury. Note that in DMEM animals (A,B) there is no separation between the two membranes whereas in hADSCs -treated animals (C,D) these membranes are separated (arrows in D). E) Confocal images of a horizontal section immunostained with anti-pan-laminin (green) and RECA-1(red). F -F) Confocal imagens of sequential optical sections immunostained with anti-pan-laminin (green) and DAPI (blue) showing the extravasation of cells from the blood vessels. Bars: C, F = 50 um B, D, E = 25 um.From: Menezes K, Nascimento MA, Gon§alves JP, Cruz AS, Lopes DV, et al. (2014) Human Mesenchymal Cells from Adipose Tissue Deposit Laminin and Promote Regeneration of Injured Spinal Cord in Rats. PLoS ONE 9(5): e96020.
Mouse Anti-RECA-1 Monoclonal Antibody – Cat# MBS213213

Testing Data of anti-RECA-1 antibody

Published customer image: Effect of clustered ephrin-A1-Fc on vascular formation in the rat striatum. (A) Distribution of BrdU(+) endothelial cells. Brain of the unilaterally lesioned rats 6 weeks after infusion of clustered ephrin-A1-Fc were sectioned coronally and stained for BrdU and Rat Endothelial Cell Antigen-1 (RECA-1). Numbers of the BrdU(+) cells and BrdU(+)&RECA-1(+) cells were counted as describe in the Materials and Methods. Total numbers of BrdU(+) cells in 8 animals are shown on the top, and percentages of RECA-1(+) cells among BrdU(+) cells are shown on the bottom. Error bars represent SD. *p
Mouse Anti-RECA-1 Monoclonal Antibody, Testing Data – Cat# MBS213213

Testing Data of anti-RECA-1 antibody

Published customer image: ChABC and GF treatments attenuate the proliferation of microglia/macrophages and promote the generation of new endothelial cells after SCI. (A -D) Representative confocal images of BrdU+/NG2+ macrophages/microglia marked with Iba-1 in the injured spinal cord (arrows). (E -F) Under baseline SCI condition, macrophages/microglia comprised about 25% and 17% of BrdU+/NG2+ cells in rostral and caudal points to the injury center, respectively. After treatment with ChABC and/or GFs, we found a reduction in the number of BrdU+/NG2+/IbA-1+ cells that was statistically significant for ChABC and ChABC+GFs treatment groups relative to the vehicle group. (G -J) Representative confocal images show newly generated endothelial cells marked by Reca-1 and NG2 among BrdU+ cells. Reca-1 positive endothelial cells comprised a subpopulation of proliferating NG2+ cells after SCI (J). (K -L) Quantification of BrdU+/NG2+/Reca-1+ cells showed a significant number of newly generated endothelial cells after treatment with ChABC and/or GFs at both rostral and caudal points to the injury center compared to the vehicle group. *p
Mouse Anti-RECA-1 Monoclonal Antibody, Testing Data – Cat# MBS213213

Testing Data of anti-RECA-1 antibody

Published customer image:Morphology of microvessels stained with RECA-1 in Abeta 1-42-injected hippocampus. Panels show morphological features including fragments, looping microvessels, and vessels with knob-like and uneven diameters. The scale bar represents 40?um.From: Jantaratnotai N, Ryu JK, Schwab C, McGeer PL, McLarnon JG. Comparison of Vascular Perturbations in an Abeta-Injected Animal Model and in AD Brain. Int J Alzheimers Dis. 2011;2011:918280.
Mouse Anti-RECA-1 Monoclonal Antibody, Testing Data – Cat# MBS213213

Testing Data of anti-RECA-1 antibody

Published customer image:Representative patterns of RECA-1 staining in rat hippocampus. (a) Microvessels in control (PBS) injected rat hippocampus (left panel) and microvessels in Abeta1-42-injected hippocampus (right panel). Scale bar is for 70um. (b) Bar graph for the number of microvessels/mm2 (n = 5 each). (c) Bar graph for microvessel length (n = 5 each). *P = 0.05 for Abeta1-42 versus PBS.From: Jantaratnotai N, Ryu JK, Schwab C, McGeer PL, McLarnon JG. Comparison of Vascular Perturbations in an Abeta-Injected Animal Model and in AD Brain. Int J Alzheimers Dis. 2011;2011:918280.
Mouse Anti-RECA-1 Monoclonal Antibody, Testing Data – Cat# MBS213213

Testing Data of anti-RECA-1 antibody

Published customer image: AdV-ZFP-VEGF results in increased vessel counts and angiogenesis. (A) Left panel: Illustration of the area of spinal cord areas used for RECA-1 counting (2 grey matter areas, 2 white matter areas). (B) Representative sections taken 2 mm rostral to the epicenter from a AdV-ZFP-VEGF treated and AdV-eGFP control animal respectively immunostained with RECA-1 at 10 days after SCI; scale 100 um. An increased number of vessels were observed in the AdV-ZFP-VEGF treated group. (C) Bar graph illustrating the RECA-1 positive cell counts 10 days after SCI. AdV-ZFP-VEGF administration resulted in a significant increase in vascular counts (2 mm and 4 mm away from the epicenter) as compared with the control group. (D) Representative confocal image from an ADV-ZFP-VEGF treated animal at 5 days post-injury. Image was taken at 2 mm rostral from the epicenter, and shows double-labeled cells. Cells were stained for endothelial cells (RECA-1, green) and proliferation (Ki67, red). Scale bar = 50 um (30 um for magnified panel). (E) Angiogenesis was assessed by quantifying Ki67/RECA-1 co-labeled vessels. Data is presented at the percentage of RECA-1+ vessels that were also Ki67+, with an overall average increase of 10% vascular proliferation observed in the animals receiving AdV-ZFP-VEGF administration. All data are presented as mean +/- SEM, and was analyzed by Two-way ANOVA (Holm-Sidak post-hoc). Angiogenesis data were analyzed by performing an arcsine transformation of the values, prior to Two-way ANOVA and post-hoc testing. *p
Mouse Anti-RECA-1 Monoclonal Antibody, Testing Data – Cat# MBS213213

Testing Data of anti-RECA-1 antibody

Published customer image: Pyruvate reduces R/M hypoglycemia-induced cortical blood vessel loss. (A) Bright field photomicrographs from coronal sections of cortex demonstrate loss of blood vessels at three days after R/M hypoglycemia by RECA-1 (rat endothelial cell antigen 1) staining. Panels show the progression of blood vessel changes in the parietal (PT Ctx) and perirhinal (PRh Ctx) cortex. After R/M hypoglycemia, blood vessels showed decreased density compared to sham-operated rats. Intraperitoneal injection of pyruvate as an adjuvant to glucose at ten minutes after R/M hypoglycemia reduced blood vessel disappearance. Scale bar = 100 um. (B) Graph represents the % area of RECA-1 immunoreactivity in the parietal and perirhinal cortex. Data are means +/- s.e.m., n=5-6 from each group, *P
Mouse Anti-RECA-1 Monoclonal Antibody, Testing Data – Cat# MBS213213

Testing Data of anti-RECA-1 antibody

Published customer image:Endothelial cell number and capillary length post radiation. (A) Representative images of sections from the corpus callosum immunostained for rat endothelial cell antigen (RECA) at various time points post radiation. RECA expression declines immediately post radiation but is restored and maintained through 15 months. Stereological estimates of the number of capillary segments in the cortex (B) and corpus callosum (C) and of capillary length in both regions (D, E). (*** p
Mouse Anti-RECA-1 Monoclonal Antibody, Testing Data – Cat# MBS213213

Testing Data of anti-RECA-1 antibody

Published customer image: Transduction of AdV-eGFP/AdV-ZFP-VEGF into the spinal cord. (A) Photomicrographs showing a transverse section of rat spinal cord obtained adjacent to the injury site 10 days after spinal cord injury and AdV-eGFP injection. eGFP signal was detected in both the gray matter and white matter. (B) High-power (63X) confocal images show that the AdV-eGFP vector (green) transfected neurons (NeuN), astrocytes (GFAP), oligodendrocytes (CC1) and endothelial cells (RECA-1). Cells have been counter-stained with DAPI (blue) as nuclear marker. (C) Bar graph displays quantification of transduced cell types +/- SEM, as identified by the cell-specific markers NeuN, GFAP, RECA-1 and CC1. (D) Evaluation of AdV-ZFP-VEGF gene transfer. Western blot showed that the NF?B p65 rabbit polyclonal antibody recognizes the p65 activation domain in the AdV-ZFP-VEGF treated animals. The higher molecular weight bands are endogenous NF?Bp65 fragments, which are also recognized by the antibody; however, these bands are present in both the control and treatment groups. The lower band (arrow) corresponds to the AdV-ZFP-VEGF and was only present in the treated animals. Lower panel shows actin expression as a protein control. Scale bar: 1000 um for A; 100 um for B.From: Figley SA, Liu Y, Karadimas SK, Satkunendrarajah K, Fettes P, et al. (2014) Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury. PLoS ONE 9(5): e96137.
Mouse Anti-RECA-1 Monoclonal Antibody, Testing Data – Cat# MBS213213

Testing Data of anti-RECA-1 antibody

Published customer image: Effect of clustered ephrin-A1-Fc on vascular formation in the rat striatum. Clustered ephrin-A1-Fc was injected into the lesioned side of the lateral ventricle in the unilaterally lesioned rats. Brains taken 6 weeks after injection were sectioned coronally and stained for GFAP (green) and RECA-1 (red) and with DAPI (nuclei; blue). The rectangular insets are shown in Fig. 8B. Scale bar: 100 um.From: Jing X, Miwa H, Sawada T, Nakanishi I, Kondo T, et al. (2012) Ephrin-A1-Mediated Dopaminergic Neurogenesis and Angiogenesis in a Rat Model of Parkinson's Disease. PLoS ONE 7(2): e32019.
Mouse Anti-RECA-1 Monoclonal Antibody, Testing Data – Cat# MBS213213

Other Notes

Small volumes of anti-RECA-1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Additional Details

NCBI/Uniprot data below describe general gene information for RECA-1. It may not necessarily be applicable to this product.

Protein Family

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000